Rocket Pharmaceuticals
RCKT
175 hedge funds and large institutions have $1.83B invested in Rocket Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 44 reducing their positions, and 17 closing their positions.
224% more call options, than puts
Call options by funds: $24.7M | Put options by funds: $7.61M
80% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 44
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
71% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 17
21% more capital invested
Capital invested by funds: $1.52B → $1.83B (+$315M)
16.12% more ownership
Funds ownership: 94.9% → 111.02% (+16%)
7% more funds holding
Funds holding: 164 → 175 (+11)
Top Buyers
Top Sellers
RCKT Hedge Fund Activity: Q3 2023 in Review
175 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2023, worth a combined $1.83B — up 21% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RCKT positions and 17 closed out — a net gain of 12 holders — while 79 added to existing stakes and 44 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $52.4M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $23.8M sold.
- 175 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2023, up from 164 in Q2 2023.
- Funds reported $1.83B of Rocket Pharmaceuticals stock for Q3 2023, up 21% quarter-over-quarter.
- 29 funds opened new Rocket Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of +12 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2023 was Wellington Management Group, an estimated $52.4M added.
- The largest Rocket Pharmaceuticals seller in Q3 2023 was Lord, Abbett & Co, an estimated $23.8M sold.
Based on aggregated 13F filings for Q3 2023.